Bluejay Therapeutics Reports First Patient Enrolment in P-III (AZURE-2) Trial of Brelovitug for Chronic Hepatitis D

Shots:Bluejay Therapeutics has enrolled its first patient in the P-III (AZURE-2) trial assessing brelovitug (300mg, SC, QW) vs Hepcludex (bulevirtide) for the treatment of chronic hepatitis DTrial will assess the proportion of participants achieving a composite response at Wk. 48, defined as undetectable hepatitis D virus RNA along with normalization of alanine aminotransferase…

ByRidhi RastogiSeptember 5, 2025

INSIGHTS+

Disease of the Month: Hepatitis – D Disease

Hepatitis D is a liver infection caused by the Hepatitis D virus (HDV) which causes the liver to become inflamed. It is also known by name of Hepatitis Delta virus or Delta Hepatitis1. Hepatitis D is a double infection as HDV requires the Hepatitis B virus (HBV) to replicate itself, therefore in the absence of…

BySenior EditorJuly 28, 2022

Bluejay Therapeutics Reports First Patient Enrolment in P-III (AZURE-2) Trial of Brelovitug for Chronic Hepatitis D

Disease of the Month: Hepatitis – D Disease

Contact US

OUR INFORMATION

FOLLOW US